Homology Medicines FIXX Stock
Homology Medicines Price Chart
Homology Medicines FIXX Financial and Trading Overview
| Homology Medicines stock price | 0.93 USD |
| Previous Close | 1.03 USD |
| Open | 1.01 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 1800 |
| Day's Range | 0.99 - 1.05 USD |
| 52 Week Range | 0.86 - 3.3 USD |
| Volume | 91.23K USD |
| Avg. Volume | 118.75K USD |
| Market Cap | 57.79M USD |
| Beta (5Y Monthly) | -0.072535 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7 USD |
FIXX Valuation Measures
| Enterprise Value | -63129232 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.7246377 |
| PEG Ratio (5 yr expected) | 0.06 |
| Price/Sales (ttm) | 18.015835 |
| Price/Book (mrq) | 0.3805175 |
| Enterprise Value/Revenue | -19.679 |
| Enterprise Value/EBITDA | 0.517 |
Trading Information
Homology Medicines Stock Price History
| Beta (5Y Monthly) | -0.072535 |
| 52-Week Change | -44.13% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.3 USD |
| 52 Week Low | 0.86 USD |
| 50-Day Moving Average | 1.01 USD |
| 200-Day Moving Average | 1.38 USD |
FIXX Share Statistics
| Avg. Volume (3 month) | 118.75K USD |
| Avg. Daily Volume (10-Days) | 81.08K USD |
| Shares Outstanding | 57.79M |
| Float | 30.78M |
| Short Ratio | 2.92 |
| % Held by Insiders | 9.18% |
| % Held by Institutions | 47.46% |
| Shares Short | 277.46K |
| Short % of Float | 0.54% |
| Short % of Shares Outstanding | 0.47% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -3839.58% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -30.25% |
| Return on Equity (ttm) | -60.24% |
Income Statement
| Revenue (ttm) | 3.21M USD |
| Revenue Per Share (ttm) | 0.06 USD |
| Quarterly Revenue Growth (yoy) | 0% |
| Gross Profit (ttm) | -95143000 USD |
| EBITDA | -122004000 USD |
| Net Income Avi to Common (ttm) | -125954000 USD |
| Diluted EPS (ttm) | -2.02 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 150.02M USD |
| Total Cash Per Share (mrq) | 2.6 USD |
| Total Debt (mrq) | 29.1M USD |
| Total Debt/Equity (mrq) | 19.16 USD |
| Current Ratio (mrq) | 8.299 |
| Book Value Per Share (mrq) | 2.628 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -109031000 USD |
| Levered Free Cash Flow (ttm) | -65527752 USD |
Profile of Homology Medicines
| Country | United States |
| State | MA |
| City | Bedford |
| Address | One Patriots Park |
| ZIP | 01730 |
| Phone | 781 301 7277 |
| Website | https://www.homologymedicines.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 92 |
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. The company's various set of AAVHSCs allows company to precisely target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, blood-brain-barrier, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Q&A For Homology Medicines Stock
What is a current FIXX stock price?
Homology Medicines FIXX stock price today per share is 0.93 USD.
How to purchase Homology Medicines stock?
You can buy FIXX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Homology Medicines?
The stock symbol or ticker of Homology Medicines is FIXX.
Which industry does the Homology Medicines company belong to?
The Homology Medicines industry is Biotechnology.
How many shares does Homology Medicines have in circulation?
The max supply of Homology Medicines shares is 3.23M.
What is Homology Medicines Price to Earnings Ratio (PE Ratio)?
Homology Medicines PE Ratio is 0.00000000 now.
What was Homology Medicines earnings per share over the trailing 12 months (TTM)?
Homology Medicines EPS is 0 USD over the trailing 12 months.
Which sector does the Homology Medicines company belong to?
The Homology Medicines sector is Healthcare.
Homology Medicines FIXX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}